European Leukemia Trial Registry
Trial: MDS Lenalidomide I

More Details
Title Lenalidomide vs Placebo in RBC-dependent low- or intermediate-1 risk MDS with 5q-
Scientific Title A Multicenter, randomized, double-blind, placebo-controlled, 2-arm study of the efficacy and safety of 2 doses of lenalidomide versus placebo in red blood cell (RBC) transfusion-dependent subjects with low -or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion (DEL) 5q[31] cytogenetic abnormality. (CC-5013-MDS-004)
Short Title MDS Lenalidomide I
Trialgroup Nordic MDS
Type of Trial multicentric, randomized
Disease Myelodysplastic Syndrome(MDS) Low risk and intermedia I
Age >= 18 years
Status Closed
Start of Recruitment 01.08.2005
Leader Hellström-Lindberg, Prof. Dr. med., Eva
Contactperson

principal investigator
Hellström-Lindberg, Prof. Dr. med., Eva
Tel: +46 (0)8 585 82506
Fax: +46 (0)8 774 8725
Email: eva.hellstrom-lindberg@medhs.ki.se

principal investigator
Olsson, Dr. med., Anna
Tel: +46 (0)8 585 82506
Fax: +46 (0)8 774 8725
Email: eva.hellstrom-lindberg@medhs.ki.se

principal investigator
Nilsson, Dr. med., Lars
Tel: +46 (0)8 585 82506
Fax: +46 (0)8 774 8725

Centre of Trial University of Stockholm, Karolinska Institutet; Sweden
Shortprotocol Shortprotocol
created 06.03.2007 Deniz Gökbuget
changed 20.03.2015 Hanna Ebert
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org